The influence of chromium chloride–containing milk to glycemic control of patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial

Pei, Dee; Hsieh, Chang-Hsun; Hung, Yi‐Jen; Li, Jer-Chuang; Lee, Chien-Hsing; Kuo, Shi‐Wen

doi:10.1016/j.metabol.2006.02.021

Cited by 40 publications

(33 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…22 Cefalu et al (2010) 23 Chen et al (2014) 24 Crawford et al (1999) 25 Evans (1989) 26 Ghosh et al (2002) 27 Gunton et al (2005) 28 Grant and McMullen. (1982) 29 Grant et al (1997) 30 Hermann et al (1998) 31 Hermann et al (1994) 32 Jain et al (2012) 40 Lee and Reasner (1994) 41 Li et al (1992) 42 Li (1994) 43 45 Martinez et al (1985) 46 Mossop (1983) 47 Offenbacher and Pi-Sunyer (1980) 48 Offenbacher et al (1985) 49 Pasman et al (1997) 50 Pei et al (2006) 51 Rabinovitz et al (1983) 52 Rabinovitz et al (2004) 53 Racek et al (2006) 54 Riales et al (1981) 55 Singer and Geohas (2006) 56 Sharma et al (2011) 57 Sherman et al (1968) 58 Thomas and Gropper (1996) 59 Urberg and Zemel (1987) 60 …”

Section: Studies Measuring Hba1cmentioning

confidence: 99%

Chromium supplements for glycemic control in type 2 diabetes: limited evidence of effectiveness

2016

View full text Add to dashboard Cite

Some adults with type 2 diabetes mellitus (T2DM) believe that chromium-containing supplements will help control their disease, but the evidence is mixed. This narrative review examines the efficacy of chromium supplements for improving glycemic control as measured by decreases in fasting plasma glucose (FPG) or hemoglobin A1c (HbA1c). Using systematic search criteria, 20 randomized controlled trials of chromium supplementation in T2DM patients were identified. Clinically meaningful treatment goals were defined as an FPG of 7.2 mmol/dL, a decline in HbA1c to 7%, or a decrease of 0.5% in HbA1c. In only a few randomized controlled trials did FPG (5 of 20), HbA1c (3 of 14), or both (1 of 14) reach the treatment goals with chromium supplementation. HbA1c declined by 0.5% in 5 of 14 studies. On the basis of the low strength of existing evidence, chromium supplements have limited effectiveness, and there is little rationale to recommend their use for glycemic control in patients with existing T2DM. Future meta-analyses should include only high-quality studies with similar forms of chromium and comparable inclusion/exclusion criteria to provide scientifically sound recommendations for clinicians.

show abstract

Section: Studies Measuring Hba1cmentioning

confidence: 99%

Chromium supplements for glycemic control in type 2 diabetes: limited evidence of effectiveness

2016

View full text Add to dashboard Cite

show abstract

“…1 (18 -27), chromium chloride (50 -600 g/day, 15 studies) (21,22,24,(27)(28)(29)(30)(31)(32)(33)(34)(35)(36)(37)(38), chromium nicotinate (200 -800 g/day, 5 studies) (39 -43), and chromium picolinate (60 -1,000 g/day, 15 studies) (39,44 -57). One study did not describe the chromium formulation (400 g/day) (58). Almost all study participants with diabetes had type 2, although in three studies this was unclear (22,29,31).…”

Section: Study Quality Assessmentmentioning

confidence: 99%

“…The majority found no effect of chromium supplementation on fasting glucose. Seven of the 17 studies reported a statistically significant reduction in fasting glucose (18,21,23,44,46,48,58), and 2 additional studies stated there were large reductions in fasting glucose but did not report statistical significance (29,52).…”

Section: Fasting Glucosementioning

confidence: 99%

“…Among the nine studies of participants with glucose intolerance (20,(32)(33)(34)39,46,53,54,58), only Anderson et al (32,33), in two separate studies of 200 g/day chromium chloride, reported statistically significant improvements in postload glucose levels with chromium supplementation: in one, an 8% reduction in 4-h AUC-Glu (but not in 3-h AUCGlu) and in the other a 1.1 mmol/l reduction in 90-min postload glucose. Other studies of all four chromium formulations reported nonsignificant changes in AUC-Glu of Ϫ21 to ϩ3% and in various timed postload glucose levels of Ϫ1.5 to ϩ0.4 mmol/l.…”

Section: Participants With Glucose Intolerancementioning

confidence: 99%

“…The three studies of chromium chloride supplementation in participants with diabetes were heterogeneous, finding a range of effects (0.0 -0.6 mmol/l) (21,28,29). All six studies of chromium picolinate in participants with either diabetes or glucose intolerance found no effect on HDL cholesterol (44,45,48,50,53,58).…”

Section: Hdl Cholesterolmentioning

confidence: 99%

See 2 more Smart Citations

Effect of Chromium Supplementation on Glucose Metabolism and Lipids

Tatsioni²,

et al. 2007

View full text Add to dashboard Cite

OBJECTIVE -A systematic review of the effect of chromium supplementation on glucose metabolism and lipid levels. RESEARCH DESIGN AND METHODS -A literature search was conducted in MED-LINE and the Commonwealth Agricultural Bureau. Eligible studies were English language randomized controlled trials of chromium supplement intake Ն3 weeks, with Ն10 participants receiving chromium. All trials with glucose metabolism outcomes and trials of individuals with diabetes or glucose intolerance for lipid outcomes were included. Meta-analyses were performed as appropriate.RESULTS -Forty-one studies met criteria, almost half of which were of poor quality. Among participants with type 2 diabetes, chromium supplementation improved glycosylated hemoglobin levels by Ϫ0.6% (95% CI Ϫ0.9 to Ϫ0.2) and fasting glucose by Ϫ1.0 mmol/l (Ϫ1.4 to Ϫ0.5) but not lipids. There was no benefit in individuals without diabetes. There were some indications of dose effect and differences among chromium formulations. Larger effects were more commonly observed in poor-quality studies. The evidence was limited by poor study quality, heterogeneity in methodology and results, and a lack of consensus on assessment of chromium status.CONCLUSIONS -No significant effect of chromium on lipid or glucose metabolism was found in people without diabetes. Chromium supplementation significantly improved glycemia among patients with diabetes. However, future studies that address the limitations in the current evidence are needed before definitive claims can be made about the effect of chromium supplementation. Diabetes Care 30:2154-2163, 2007C hromium is an essential mineral that is thought to be necessary for normal glucose and lipid homeostasis (1-3). Trivalent chromium in a complex known as glucose tolerance factor is considered the biologically active form. It was originally discovered in brewer's yeast (4). Chromium chloride, chromium nicotinate, and chromium picolinate are commonly used formulations of trivalent chromium. Chromium picolinate is a formulation designed to improve absorption (5). Severe chromium deficiency is known to cause reversible insulin resistance and diabetes (6 -8). However, the effect of chromium supplementation in individuals who are not severely chromium deficient is unclear. Manufacturers aggressively promote the benefits of chromium in the prevention and treatment of insulin resistance and its associated conditions (type 2 diabetes, dyslipidemia, and cardiovascular disease), and the public has embraced its use. Chromium supplement sales represent ϳ6% of the U.S. mineral supplement market (9).To clarify the role of chromium supplementation in the prevention and management of abnormal glucose and lipid homeostasis, we performed a systematic review of randomized controlled trials on the effect of chromium supplement intake on glucose metabolism and lipid profile. RESEARCH DESIGN AND METHODS Literature search and eligibility criteriaWe conducted a systematic review of the English-language literature on the effects of chromium supplementa...

show abstract

Is Chromium(III) Effective as a Therapeutic Agent?

Vincent

2012

The Bioinorganic Chemistry of Chromium

View full text Add to dashboard Cite

The influence of chromium chloride–containing milk to glycemic control of patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial

Cited by 40 publications

References 32 publications

Chromium supplements for glycemic control in type 2 diabetes: limited evidence of effectiveness

Chromium supplements for glycemic control in type 2 diabetes: limited evidence of effectiveness

Effect of Chromium Supplementation on Glucose Metabolism and Lipids

Is Chromium(III) Effective as a Therapeutic Agent?

Contact Info

Product

Resources

About